Stockscreener 앱 받기
1.23
4.65%
-0.06
시장 영업 전:
1.23
전일 마감가:
$1.29
열려 있는:
$1.25
하루 거래량:
135.42K
Relative Volume:
0.34
시가총액:
$33.39M
수익:
$950.10K
순이익/손실:
$-16.69M
주가수익비율:
-1.4819
EPS:
-0.83
순현금흐름:
$-15.16M
1주 성능:
-7.87%
1개월 성능:
-20.13%
6개월 성능:
+10.31%
1년 성능:
-32.04%
1일 변동 폭
$1.22
$1.30
1주일 범위
$1.1801
$1.39
52주 변동 폭
$0.86
$1.84
Femasys Inc Stock (FEMY) Company Profile
명칭
Femasys Inc
전화
770-500-3910
주소
3950 JOHNS CREEK COURT, SUWANEE
FEMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.23 | 33.39M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
494.61 | 177.21B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
221.59 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
89.61 | 44.32B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
213.35 | 31.33B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
31.35 | 16.08B | 17.28B | 108.00M | 391.00M | 0.20 |
Femasys Inc 주식(FEMY)의 최신 뉴스
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic - Asianet Newsable
HC Wainwright Reaffirms “Buy” Rating for Femasys (NASDAQ:FEMY) - Defense World
Femasys Positioned for Growth with Innovative Products and Strategic Partnerships - TipRanks
H.C. Wainwright maintains Femasys stock Buy rating, $15 target - Investing.com India
H.C. Wainwright maintains Femasys stock Buy rating, $15 target By Investing.com - Investing.com Australia
Femasys earnings missed by $0.04, revenue fell short of estimates - Investing.com Canada
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Femasys reports FY24 EPS (85c), consensus (81c) - TipRanks
Femasys Inc. FY EPS USD -0.85 - Marketscreener.com
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update - GlobeNewswire
FEMASYS Earnings Preview: Recent $FEMY Insider Trading, Hedge Fund Activity, and More - Nasdaq
FY2026 Earnings Forecast for Femasys Issued By HC Wainwright - Defense World
HC Wainwright Boosts Femasys (NASDAQ:FEMY) Price Target to $15.00 - Defense World
H.C. Wainwright raises Femasys stock price target to $15 By Investing.com - Investing.com Australia
Femasys price target raised to $15 from $12 at H.C. Wainwright - Yahoo Finance
H.C. Wainwright raises Femasys stock price target to $15 - Investing.com
Femasys (FEMY) to Release Earnings on Thursday - Defense World
Femasys Gains Momentum with EU Approval and Strategic Partnerships, Boosting Buy Rating - TipRanks
Femasys Announces Partnership with CNY Fertility, National - GlobeNewswire
Femasys Secures Game-Changing Partnership: FemaSeed Now Available at 11 Leading Fertility Centers - StockTitan
Femasys’s Strategic Expansion and Promising Clinical Results Justify Buy Rating - TipRanks
Assessing Femasys: Insights From 4 Financial Analysts - Benzinga
Femasys Signs FemBloc Commercial Distribution Deals -March 18, 2025 at 09:58 am EDT - Marketscreener.com
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain - GlobeNewswire
Femasys Breaks Into European Market: First Global Deal for Revolutionary Birth Control Solution - StockTitan
HC Wainwright Reiterates “Buy” Rating for Femasys (NASDAQ:FEMY) - Defense World
H.C. Wainwright maintains Femasys stock Buy rating, $12 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Femasys stock Buy rating, $12 target - Investing.com
Femasys gains CE mark for non-surgical birth control system By Investing.com - Investing.com Australia
Femasys Achieves CE Mark for FemBloc, Paving the Way for European Market Entry and Justifying Buy Rating - TipRanks
Femasys Receives CE Mark for FemBloc Non-Surgical Permanent Birth Control System - Femtech Insider
Femasys gains CE mark for non-surgical birth control system - Investing.com
Femasys Announces FemBloc Delivery System Approval in - GlobeNewswire
Revolutionary Breakthrough: Femasys Gets EU Approval for Non-Surgical Permanent Birth Control - StockTitan
Femasys announces FemBloc delivery system approval in Europe - TipRanks
Femasys Offers a Fresh Take on Women’s Reproductive Healthcare - MD+DI
Femasys gains UK approval for women's health products - MSN
Femasys’s FemBloc: A Promising Investment in Permanent Contraceptive Innovation - TipRanks
Femasys announces publication of ‘positive’ results from FemBloc trials - TipRanks
Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire
Could This Non-Surgical Birth Control Method Replace Traditional Sterilization? Clinical Trials Say Yes - StockTitan
Femasys Inc (FEMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.94%
1.87%
자본화:
|
볼륨(24시간):